| Mitsubishi Tanabe Pharma GmbH, Düsseldorf, Zweigniederlassung Lenzburg - Radicava, Suspension zum Einnehmen | | 68016 | | 01 | | Radicava | | Suspension zum Einnehmen | | N07XX14 | | Edaravone | | 01.05.2023 | | |
| | Composition | | edaravonum 105 mg, poly(alcohol vinylicus), xanthani gummi, E 222 5 mg, cysteini hydrochloridum monohydricum, natrii hydroxidum q.s. ad pH, acidum phosphoricum q.s. ad pH, sorbitolum 2000 mg, simeticoni emulsio, aqua purificata, q.s. ad suspensionem pro 5 ml, natrium 1.10 mg. | | Packungsbestandteile | | Suspension (orale) | | | | | | Principe actif | Concentr. |
|---|
| Edaravonum | 105 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| Cystein Hydrochloride Monohydrate | | | | E 222 | 5 mg | conserv. | | Sodium Hydroxide | | | | Poly(Alcohol Vinylicus) | | | | Xanthani Gummi | | |
|
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | 50 ml | DDP | DDP | B | | Non | | 002 | 2 x 35 ml | DDP | DDP | B | | Non |
|
|
